Polymer-lipid microencapsulated gases for use as imaging agents

• US 5,837,221 A
• Filed: 07/29/1996
• Issued: 11/17/1998
• Est. Priority Date: 07/29/1996
• Status: Expired due to Term

• Current Assignee: Acusphere Incorporated
• Original Assignee: Acusphere Incorporated
• Inventors: Bernstein, Howard, Straub, Julie Ann, Church, Charles C., Brush, Henry T.
• Primary Examiner(s): Hollinden, Gary E.
• Assistant Examiner(s): Hartley, Michael G.
• Application Number:
  US08/681,710
• Time in Patent Office: 841 Days
• Field of Search: 424/9.52, 424/9.51, 424/9.5, 424/450, 424/489, 424/497, 424/498, 424/502, 424/501, 424/499, 128/662.02, 428/402, 428/402.24, 427/213.3, 264/4, 264/4.7, 600/458
• US Class Current: 424/9.52
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61K 49/223 Microbubbles, hollow microspheres, free gas bubbles, gas microspheres

Abstract

It has been discovered that the incorporation of gases, especially fluorinated gases such as perfluorocarbons, into microparticles formed from the combination of a natural or synthetic polymer and lipid have significantly enhanced echogenicity as compared with microparticles not including the lipid. Compounds other than lipids which are hydrophobic and limit the penetration and/or uptake of water into the microparticles can also be incorporated into the microparticles to enhance echogenicity. In the preferred embodiment, the polymers are synthetic biodegradable polymers. The microparticles are manufactured with a diameter suitable for the targeted tissue to be imaged, for example, with a diameter of between 0.5 and 8 microns for intravascular administration, and a diameter of between 0.5 and 5 mm for oral administration for imaging of the gastrointestinal tract or other lumens. Preferred polymers are polyhydroxy acids such as polylactic acid-co-glycolic acid, most preferably conjugated to polyethylene glycol or other materials inhibiting uptake by the reticuloendothelial system (RES). The most preferred lipids are phospholipids, preferably dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine, dilignoceroylphatidylcholine (DLPC), incorporated at a ratio of between 0.01-30 (w lipid/w polymer), most preferably between 0.1-10 (w lipid/w polymer). Microparticles for imaging using other detectable agents can be similarly manufactured.

Claims

1. A method for making microparticles for diagnostic imaging, wherein the microparticles are formed of a biocompatible polymer and have incorporated therein gas, the improvement comprising

(a) incorporating into the polymer a hydrophobic compound by either dissolving the polymer and hydrophobic compound in an organic solvent or melting the polymer with the hydrophobic compound, prior to forming the microparticles, and

(b) forming the microparticles by either removing the polymer solvent or cooling the polymer,

wherein the hydrophobic compound is mixed with the polymer in the microparticle in an amount effective to increase the echogenicity of the microparticle as compared to the echogenicity of the microparticle without the hydrophobic compound and

wherein the hydrophobic compound is selected from the group consisting of fatty acids, fatty acid alcohols, fatty acid anhydrides, hydroxy fatty acids, prostaglandins, phospholipids, sphingolipids, steroids and steroid derivatives, fat soluble vitamins, terpenes, tryptophan, tyrosine, isoleucine, leucine, valine, alkyl paraben, and benzoic acid.

2. The method of claim 1 wherein the hydrophobic compound is incorporated with the polymer at a ratio of between 0.01 and 30 by weight of hydrophobic compound to weight of polymer.

3. The method of claim 2 wherein the hydrophobic compound is a lipid incorporated with the polymer at a ratio of between 0.01 and 30 (weight lipid/weight polymer).

4. The method of claim 1 wherein the lipid is a phospholipid selected from the group consisting of phosphatidic acids, phosphatidyl cholines with both saturated and unsaturated lipids, phosphatidyl ethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, lysophosphatidyl derivatives, cardiolipin, and β

-acyl-y-alkyl phospholipids.

5. The method of claim 4, wherein the phospholipid is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipentadecanoylphosphatidylcholine dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, ditricosanoylphosphatidylcholine, dilignoceroylphatidylcholine;

and phosphatidylethanolamines.

6. The method of claim 1 wherein the gas is selected from the group consisting of fluorinated gases, oxygen, xenon, argon, helium, and air.

7. The method of claim 6 wherein the gas is selected from the group consisting of CF₄, C₂ F₆, C₃ F₈, C₄ F₈, C₄ F₁₀, SF₆, C₂ F₄, and C₃ F₆.

8. The method of claim 7 wherein the gas is octafluoropropane.

9. The method of claim 1 wherein the microparticle is formed of a synthetic polymer.

10. The method of claim 1 wherein the microparticle is formed of a natural polymer.

11. The method of claim 1 wherein the microparticle is formed of a bioadhesive polymer.

12. The method of claim 9 wherein the microparticle is formed of a synthetic polymer selected from the group consisting of poly(hydroxy acids), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, poly(vinyl alcohols), poly(vinyl acetate), polystyrene, polyurethanes and co-polymers thereof, synthetic celluloses, polyacrylic acids, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone), ethylene vinyl acetate, copolymers and blends thereof.

13. A composition for diagnostic imaging comprising biocompatible polymeric microparticles incorporating a gas which are formed by the steps of

(a) dissolving the polymer and a hydrophobic compound in an organic solvent or melting the polymer and the hydrophobic compound, prior to forming the microparticles,

(b) forming the microparticles by removing the solvent or cooling the polymer,

wherein the hydrophobic compound is mixed with the polymer in the microparticle in an amount effective to increase the echogenicity of the microparticle as compared to the echogenicity of the microparticle without the hydrophobic compound, and

wherein the hydrophobic compound is selected from the group consisting of fatty acids, fatty acid alcohols, fatty acid anhydrides, hydroxy fatty acids, prostaglandins, phospholipids, sphingolipids, steroids and steroid derivatives, fat soluble vitamins, terpenes, tryptophan, tyrosine, isoleucine, leucine, valine, alkyl paraben, and benzoic acid.

14. The microparticles of claim 13 wherein the hydrophobic compound is incorporated with the polymer at a ratio of between 0.01 and 30 by weight of hydrophobic compound to weight of polymer.

15. The microparticles of claim 14 wherein the hydrophobic compound is a lipid incorporated with the polymer at a ratio of between 0.01 and 30 (weight lipid/weight polymer).

16. The microparticles of claim 13 wherein the lipid is a phospholipid selected from the group consisting of phosphatidic acids, phosphatidyl cholines with both saturated and unsaturated lipids, phosphatidyl ethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, lysophosphatidyl derivatives, cardiolipin, and β

-acyl-y-alkyl phospholipids.

17. The microparticles of claim 16 wherein the phospholipid is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipentadecanoylphosphatidylcholine dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, ditricosanoylphosphatidylcholine, dilignoceroylphatidylcholine;

and phosphatidylethanolamines.

18. The microparticles of claim 13 wherein the gas is selected from the group consisting of fluorinated gases, oxygen, xenon, argon, helium, and air.

19. The microparticles of claim 18 wherein the gas is selected from the group consisting of CF₄, C₂ F₆, C₃ F₈, C₄ F₈, C₄ F₁₀, SF₆, C₂ F₄, and C₃ F₆.

20. The microparticles of claim 19 wherein the gas is octafluoropropane.

21. The microparticles of claim 13 wherein the microparticle is formed of a synthetic polymer.

22. The microparticles of claim 21 wherein the polymer is selected from the group consisting of poly(hydroxy acids), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, poly(vinyl alcohols), poly(vinyl acetate), polystyrene, polyurethanes and co-polymers thereof, synthetic celluloses, polyacrylic acids, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone), ethylene vinyl acetate, copolymers and blends thereof.

23. The microparticles of claim 15 wherein the lipid is liquified with the polymer to form the microparticles.

24. The microparticles of claim 23 wherein the lipid and the polymer are dissolved in a solvent for both, then formed into microparticles.

25. The microparticles of claim 23 wherein the gas is incorporated into the microparticle after the polymer and lipid have solidified.

26. The microparticles of claim 13 wherein the polymer is a natural polymer selected from the group consisting of proteins and polysaccharides.

27. In a method for increasing the hydrophobicity of microparticles formed of a biocompatible hydrophobic polymer and having incorporated therein a gaseous imaging agent, the improvement comprising

dissolving the polymer and a hydrophobic compound in an organic solvent or melting the polymer and a hydrophobic compound,

removing the solvent or cooling the polymer to form the microparticles,

wherein the hydrophobic compound is mixed with the polymer in the microparticle in an amount effective to increase the echogenicity of the microparticle as compared to the echogenicity of the microparticle without the hydrophobic compound.

28. The method of claim 27, wherein the hydrophobic compound is selected from the group consisting of fatty acids, fatty acid alcohols, fatty acid anhydrides, hydroxy fatty acids, prostaglandins, phospholipids, sphingolipids, steroids and steroid derivatives, fat soluble vitamins, terpenes, tryptophan, tyrosine, isoleucine, leucine, valine, alkyl paraben, and benzoic acid.